FDA Approves New Treatment for CLL
The FDA has granted accelerated approval for GlaxoSmithKline and Genmab’s Arzerra™ (ofatumumab) for people with chronic lymphocytic leukemia whose cancer is no longer being controlled by other forms of chemotherapy. Arzerra is a monoclonal antibody that causes the body’s immune response to fight against both normal and malignant B cells.
The manufacturer is currently conducting a clinical trial in people with CLL to confirm that the addition of Arzerra to standard chemotherapy delays the progression of the disease.
♦ ♦ ♦ ♦ ♦
This article was originally published in Coping® with Cancer magazine, January/February 2010.